Scalable differentiation of human cardiac organoids from iPSCs generates cardiac tissues for cardiac cell therapy - PubMed
4 hours ago
- #myocardial-infarction
- #cardiac-organoids
- #iPSC-therapy
- Cardiac organoids (COs) derived from iPSCs offer potential for cell-based heart therapies by improving engraftment.
- Differentiation into mature COs with cardiomyocytes, fibroblasts, and endothelial cells occurs within 20 days, featuring organized sarcomeres and gap junctions.
- A bioreactor strategy enables scalable production for high cell densities required in regenerative medicine.
- Transplantation of COs into pig hearts with acute infarction showed successful engraftment without arrhythmic events over 8-30 days.
- CO treatment enhanced cardiac function, reduced scar size, and downregulated pro-fibrotic signaling in the infarcted area.
- This technology provides a platform for developing cardiac cell therapies targeting myocardial infarction.